Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Drug Profiles/Updates
Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Read More
Online First
FDA Approves Bridion to Reverse Effects of Neuromuscular Blocking Drugs Used During Surgery
Read More
Concise Review of Obinutuzumab in the Treatment of Patients with Chronic Lymphocytic Leukemia
Read More
Omacetaxine Mepesuccinate: A Novel mRNA Translation Inhibitor for Drug-Resistant Chronic Myelogenous Leukemia
Read More
FLAG-IDA Regimen-Induced Thrombotic Microangiopathy: A Case Report
Read More
The Effect of Atazanavir on Doxorubicin Pharmacokinetics: A Case Report
Read More
Palifermin Use for the Prevention of Chemotherapy-Induced Oral Mucositis in Anal Cancer: A Case Report
Read More
Ipilimumab: Unique Responses, Toxicities, and Recommendations for the Use of the First Anti–CTLA-4 Therapy in Patients with Melanoma
Read More
A Review of PARP Inhibitors in Clinical Development
Read More
Reversible Posterior Leukoencephalopathy Syndrome Secondary to Bevacizumab
Read More
1
2
3
4
Page 4 of 4
Results 31 - 40 of 40